Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 5/20 | 0.56 |
| ▸ | HTT | P42858 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2087952 | 0.88 | CETP (0.67) | CETPLMNAMAPTTP53KMT2A | |
| SCHEMBL5706504 | 0.87 | CETP (0.71) | CETPLMNAKMT2AKDM4EL3MBTL1 | |
| SCHEMBL1555152 | 0.86 | GAA (0.54) | CETPGAAHTTLMNAMAPT | |
| SCHEMBL10027976 | 0.82 | LMNA (0.59) | CETPGAAHTTLMNAMAPT | |
| SCHEMBL19771462 | 0.82 | TRPV1 (0.54) | CETPGAAMAPTKMT2AKDM4E | |
| SCHEMBL27997031 | 0.82 | GAA (0.50) | CETPGAAHTTLMNAMAPT | |
| SCHEMBL6351755 | 0.80 | PDK1 (0.71) | GAAHTTLMNAMAPT | |
| SCHEMBL15667994 | 0.80 | CA12 (0.52) | CETPNPC1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL7299817 | 0.80 | GAA (0.56) | GAAHTTLMNAMAPTNPC1 | |
| SCHEMBL2301094 | 0.80 | CETP (0.68) | CETPLMNAKMT2AKDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4070795-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | Salk Institute for Biological Studies (US) | 2022-10-12 | — | — | EP | disclosed |
| EP-3185868-B1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INST FOR BIOLOGICAL STUDI (US) | 2022-04-06 | — | — | EP | disclosed |
| US-10774092-B2 | ULK1 inhibitors and methods using same | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-09-15 | — | — | US | disclosed |
| US-10774092-B2 | ULK1 inhibitors and methods using same | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-09-15 | — | — | US | disclosed |
| US-10689397-B2 | ULK1 inhibitors and methods using same | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-06-23 | — | — | US | disclosed |
| US-10689397-B2 | ULK1 inhibitors and methods using same | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190284207-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2019-09-19 | — | — | US | disclosed |
| US-20190284207-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2019-09-19 | — | — | US | disclosed |
| US-20190248806-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2019-08-15 | — | — | US | disclosed |
| US-20190248806-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2019-08-15 | — | — | US | disclosed |
| US-7375228-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-7375228-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-7250514-B1 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250514-B1 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-7169801-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169801-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-20040266769-A1 | Histone deacetylase inhibitors | SYRRX, INC. | 2004-12-30 | — | — | US | disclosed |
| US-20040266769-A1 | Histone deacetylase inhibitors | SYRRX, INC. | 2004-12-30 | — | — | US | disclosed |
| EP-0428899-B1 | Use of magenta couplers exhibiting reduced stain | FUJI PHOTO FILM CO LTD (JP) | 1997-10-01 | — | — | EP | disclosed |
| EP-0428899-A2 | Silver halide color photographic material and method for processing thereof | FUJI PHOTO FILM CO., LTD. (JP) | 1991-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689397-B2 | ULK1 inhibitors and methods using same | ULK1, ULK2, ULK3 | CETP 2657/4885GAA 523/4885HTT 269/4885 |
| US-20040266769-A1 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC10 | CETP 2463/4885GAA 291/4885HTT 3162/4885 |
| US-20190248806-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | ULK1, ULK2, ULK3 | CETP 2979/4885GAA 546/4885HTT 365/4885 |
| US-10774092-B2 | ULK1 inhibitors and methods using same | ULK1, ULK2, ULK3 | CETP 2657/4885GAA 523/4885HTT 269/4885 |
| US-20190284207-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | ULK1, ULK2, ULK3 | CETP 2979/4885GAA 546/4885HTT 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.